Gupta Arjun, Stewart Tyler, Bhulani Nizar, Dong Ying, Rahimi Zain, Crane Kimberli, Rethorst Chad, Beg Muhammad S
Arjun Gupta, Nizar Bhulani, Ying Dong, Zain Rahimi, Kimberli Crane, Chad Rethorst, and Muhammad S. Beg, University of Texas Southwestern Medical Center, Dallas, TX; and Tyler Stewart, Yale University, New Haven, CT.
JCO Clin Cancer Inform. 2018 Dec;2:1-10. doi: 10.1200/CCI.17.00152.
The feasibility of using physical activity monitors (PAMs) to measure functional status in patients with cancer is unclear. We aimed to determine the feasibility of using PAMs to longitudinally assess physical activity and performance status (PS) in patients with cancer.
Patients with cancer who had Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and were receiving systemic therapy were enrolled in a prospective pilot trial of PAM use. Feasibility was defined as patients using the PAM for > 50% of the observation period. We correlated PAM-reported measures with scores from ECOG PS and quality-of-life tools (Functional Assessment of Cancer Therapy-General [FACT-G], Quick Inventory of Depressive Symptoms-Self-Rated 16 [QIDS-SR16], and Brief Fatigue Inventory [BFI]) using Pearson's correlation test. Patients were surveyed regarding their experience with PAMs at study completion.
In all, 24 patients were enrolled; mean age was 54 years, 16 (67%) were women, and 19 (79%) were white. Twenty-three patients (96%) met the primary end point of feasibility. The median duration of follow-up was 69 days. Mean PAM-measured steps for ECOG PS of 0, 1, and 2 were 5,911, 1,890, and 845 steps per day, respectively ( P = .002). Minimum steps per day correlated with BFI ( r = -0.53; P < .01), FACT-G ( r = 0.45; P = .02), and QIDS-SR16 ( r = -0.57; P < .01). Eighteen patients (75%) reported a positive experience with the PAM.
PAMs are a feasible tool for measuring long-term physical activity in patients with cancer who are receiving systemic therapy. PAM-derived measures correlated with clinician-assessed PS.
使用身体活动监测器（PAM）来测量癌症患者的功能状态，其可行性尚不清楚。我们旨在确定使用PAM纵向评估癌症患者身体活动和体能状态（PS）的可行性。
将东部肿瘤协作组（ECOG）体能状态评分为0至2且正在接受全身治疗的癌症患者纳入一项使用PAM的前瞻性试点试验。可行性定义为患者在观察期的>50%时间内使用PAM。我们使用Pearson相关检验将PAM报告的测量值与ECOG体能状态评分以及生活质量工具（癌症治疗功能评估通用版[FACT-G]、抑郁症状快速自评量表16[QIDS-SR16]和简明疲劳量表[BFI]）的评分进行关联。在研究结束时对患者进行关于他们使用PAM体验的调查。
总共纳入了24名患者；平均年龄为54岁，16名（67%）为女性，19名（79%）为白人。23名患者（96%）达到了可行性的主要终点。中位随访时间为69天。ECOG体能状态评分为0、1和2的患者，PAM测量的平均每日步数分别为5911步、1890步和845步（P = 0.002）。每日最少步数与BFI（r = -0.53；P < 0.01）、FACT-G（r = 0.45；P = 0.02）和QIDS-SR16（r = -0.57；P < 0.01）相关。18名患者（75%）报告对PAM有积极体验。
PAM是一种可行的工具，可用于测量接受全身治疗的癌症患者的长期身体活动。PAM得出的测量值与临床医生评估的体能状态相关。
